Northstar Asset Management Inc. Decreases Stock Position in Novo Nordisk A/S $NVO

Northstar Asset Management Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 24.1% in the 2nd quarter, Holdings Channel reports. The firm owned 51,796 shares of the company’s stock after selling 16,450 shares during the period. Northstar Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,483,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $25,000. Transamerica Financial Advisors LLC increased its stake in Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after acquiring an additional 403 shares during the last quarter. Johnson Financial Group Inc. increased its stake in Novo Nordisk A/S by 128.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after acquiring an additional 384 shares during the last quarter. Scarborough Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Finally, Kingdom Financial Group LLC. bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Price Performance

NVO stock opened at $45.59 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $48.03 and a 200 day moving average price of $43.90. The stock has a market cap of $203.56 billion, a PE ratio of 11.15, a P/E/G ratio of 4.17 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.43 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were paid a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Analysts Set New Price Targets

NVO has been the subject of a number of recent research reports. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Four research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $64.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.